Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07069556 · ClinicalTrials.gov registry record
ColoSense Post-Approval Study
A clinical trial of Colorectal Cancer (Diagnosis), sponsored by Geneoscopy.
- Recruiting
- Registry status
- 12,500
- Enrollment target
- 1
- Study location
NCT07069556: Recruiting study of Colorectal Cancer (Diagnosis), sponsored by Geneoscopy.
NCT07069556 is a study of Colorectal Cancer (Diagnosis) that is actively recruiting participants, run by Geneoscopy. The registered enrollment target is 12,500 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07069556, a study of Colorectal Cancer (Diagnosis), is actively recruiting participants, sponsored by Geneoscopy.
- RECRUITING
- Registry status
- 12,500 participants
- Enrollment target
- 1
- Study location
Study Summary
The post-approval study (PAS) described here will supplement existing data generated in the CRC-PREVENT clinical trial. The primary outcomes of this supplemental study will include: clinical sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive value (NPV) of ColoSense.
Primary Outcome
ColoSense sensitivity for subjects with colorectal cancer (CRC), which is the percentage of individuals with a diagnosis of CRC that were detected as positive by the ColoSense test.
Conditions Studied
Interventions
- DEVICE ColoSense
Study Locations (1)
Missouri
- Decentralized Study - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12,500 participants |
| Start Date | 2025-09-05 |
| Est. Completion | 2030-09-01 |
What NCT07069556 shows while recruiting
NCT07069556 is an observational study that tracks outcomes without assigning an intervention. Its 12,500 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Colorectal Cancer (Diagnosis) appearing as the primary indexed condition, and to 1 intervention - of which ColoSense is the first listed.
NCT07069556 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT07069556 about?
NCT07069556 is a clinical study titled "ColoSense Post-Approval Study". The post-approval study (PAS) described here will supplement existing data generated in the CRC-PREVENT clinical trial. The primary outcomes of this supplemental study will include: clinical sensitivity, clinical specificity, positive predictive value (PPV), and negative predictive value (NPV) of Co...
What is the current status of trial NCT07069556?
This trial is currently recruiting. The enrollment target is 12,500 participants. The study started on 2025-09-05. Estimated completion is 2030-09-01.
What conditions does trial NCT07069556 study?
This clinical trial studies the following conditions: Colorectal Cancer (Diagnosis).
What interventions are being tested in trial NCT07069556?
The interventions under investigation include: ColoSense (DEVICE).
Who is sponsoring clinical trial NCT07069556?
This trial is sponsored by Geneoscopy, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07069556 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer (Diagnosis)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04888832 · 12,500 participants · NA
The Effect of Work Requirements in SNAP in Virginia
- NCT05452941 · 12,500 participants
A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting
- NCT07037433 · 12,800 participants · Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- NCT03586895 · 12,838 participants · NA
e-Connect: A Service System Intervention for Justice Youth at Risk for Suicide
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI